'''Sapacitabine''' is a drug undergoing research for potential use in [[chemotherapy]].<ref name="pmid18300755">{{cite journal |author1=Faderl S |author2=Gandhi V |author3=Kantarjian HM |title=Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia |journal=Curr. Opin. Hematol. |volume=15 |issue=2 |pages=101–7 |date=March 2008 |pmid=18300755 |doi=10.1097/MOH.0b013e3282f46e94 |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00062752-200803000-00006}}</ref><ref name="pmid17637678">{{cite journal  |vauthors=Serova M, Galmarini CM, Ghoul A, etal |title=Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells |journal=Br. J. Cancer |volume=97 |issue=5 |pages=628–36 |date=September 2007 |pmid=17637678 |doi=10.1038/sj.bjc.6603896 |pmc=2360357}}</ref> The company Cyclacel has developed the drug sapacitibine and hopes to reach the point of bringing it to market after clinical trials are completed.
